Equities

MeiraGTx Holdings PLC

MeiraGTx Holdings PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.93
  • Today's Change0.01 / 0.17%
  • Shares traded149.53k
  • 1 Year change+9.61%
  • Beta1.2103
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year MeiraGTx Holdings PLC had revenues fall -11.95% from 15.92m to 14.02m, though the company grew net income from a loss of 129.62m to a smaller loss of 84.03m.
Gross margin-7.72%
Net profit margin-633.05%
Operating margin-1,266.97%
Return on assets-31.12%
Return on equity-93.99%
Return on investment-39.74%
More ▼

Cash flow in USDView more

In 2023, MeiraGTx Holdings PLC increased its cash reserves by 13.10%, or 15.13m. Cash Flow from Financing totalled 84.02m or 599.44% of revenues. In addition the company used 105.37m for operations while cash from investing totalled 34.03m.
Cash flow per share-1.14
Price/Cash flow per share--
Book value per share1.23
Tangible book value per share1.22
More ▼

Balance sheet in USDView more

MeiraGTx Holdings PLC has a Debt to Total Capital ratio of 43.24%, a lower figure than the previous year's 78.19%.
Current ratio2.34
Quick ratio--
Total debt/total equity0.7619
Total debt/total capital0.4324
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.